Rosetta Genomics Gets Patent Allowance For microRNA-based Ovarian Cancer Treatment
Rosetta Genomics Ltd. (NASDAQ: ROSG) revealed that the Patent and Trademark Office in the United States has issued a notice of allowance for its patent, entitled "Compositions and methods for treatment of Ovarian Cancer." According to the company, it covered a method of treatment for ovarian cancer by administering an inhibitor of miR-27a.
Aside from that, Rosetta said the Israel Patent Office has also allowed its Application entitled "Compositions and Methods for Modulating Cell Proliferation and Cell Death," to claim use of miR-34a or its variants for treating p53-negative cancers. The company indicated that this application covered a core element of its microRNA technology in the development of cancer therapeutics in connection with p53-negative cancers. That included lymphoma, breast cancer, ovarian cancer, liver cancer, skin cancer, certain types of lung cancer, and others.
The company stated the patent was jointly owned with Yeda R&D Co. Ltd., the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel. The company added that the technology was licensed to Mirna Therapeutics.
Rosetta president and CEO, Kenneth Berlin, said, "These patent grants further strengthen our international intellectual property position and complement already granted patents. Our growing patent estate continues to be a valuable asset for Rosetta as it provides protection for our core product portfolio, supports our research and development efforts and offers multiple opportunities to monetize patents outside our core diagnostics platforms."
He continued, "We believe the new U.S. patent may be of great value in the development of new treatment options for platinum-resistant ovarian cancer patients. Our goal is to monetize this U.S. patent and the related technology through a potential partnership."
The stock traded 9 percent higher on Monday.
See more from Benzinga
Verizon Completes 5G Radio Specifications, Pre-Commercial Trials In Full Steam
Lockheed Martin's Sikorsky And Babcock Reach 10-Year Deal For S-92 Helicopter
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
